Replimune Group - REPL Stock Forecast, Price & News

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Replimune Group Price Performance

Replimune Group stock traded down $0.21 during mid-day trading on Tuesday, reaching $20.06. 4,885 shares of the company's stock were exchanged, compared to its average volume of 159,929. The business's fifty day simple moving average is $18.14 and its 200 day simple moving average is $17.30. Replimune Group has a one year low of $13.05 and a one year high of $35.93. The company has a debt-to-equity ratio of 0.06, a quick ratio of 19.46 and a current ratio of 19.46.

Replimune Group (NASDAQ:REPL - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.15). On average, analysts predict that Replimune Group will post -2.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

REPL has been the topic of a number of recent research reports. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Replimune Group in a report on Tuesday, May 24th. SVB Leerink dropped their target price on Replimune Group from $48.00 to $37.00 and set an "outperform" rating on the stock in a report on Friday. Wedbush dropped their target price on Replimune Group from $59.00 to $52.00 and set an "outperform" rating on the stock in a report on Tuesday, May 24th. Finally, Piper Sandler dropped their target price on Replimune Group from $52.00 to $44.00 in a report on Thursday, May 19th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $46.00.

Insiders Place Their Bets

In other Replimune Group news, CEO Philip Astley-Sparke sold 9,632 shares of the firm's stock in a transaction on Monday, May 16th. The stock was sold at an average price of $14.59, for a total value of $140,530.88. Following the completion of the sale, the chief executive officer now directly owns 1,401,080 shares of the company's stock, valued at $20,441,757.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Pamela Esposito sold 3,507 shares of Replimune Group stock in a transaction on Monday, May 16th. The stock was sold at an average price of $14.59, for a total value of $51,167.13. Following the completion of the transaction, the insider now directly owns 229,402 shares in the company, valued at $3,346,975.18. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Philip Astley-Sparke sold 9,632 shares of Replimune Group stock in a transaction on Monday, May 16th. The shares were sold at an average price of $14.59, for a total value of $140,530.88. Following the completion of the transaction, the chief executive officer now owns 1,401,080 shares of the company's stock, valued at $20,441,757.20. The disclosure for this sale can be found here. Insiders sold 22,899 shares of company stock valued at $334,096 over the last ninety days. 23.80% of the stock is currently owned by insiders.